Identification of ALK Gene Alterations in Urothelial Carcinoma
View/ Open
Author
Selvarajah, Shamini
Salido, Marta
de Muga, Silvia
Costa, Irmgard
Bellosillo, Beatriz
Werner, Lillian
Mullane, Stephanie
O'Brien, Robert
Barretina, Jordi
Minoche, André E.
Montagut, Clara
Himmelbauer, Heinz
Berman, David M.
Rosenberg, Jonathan E.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1371/journal.pone.0103325Metadata
Show full item recordCitation
Bellmunt, J., S. Selvarajah, S. Rodig, M. Salido, S. de Muga, I. Costa, B. Bellosillo, et al. 2014. “Identification of ALK Gene Alterations in Urothelial Carcinoma.” PLoS ONE 9 (8): e103325. doi:10.1371/journal.pone.0103325. http://dx.doi.org/10.1371/journal.pone.0103325.Abstract
Background: Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene alterations in urothelial carcinoma (UC) and its correlation with clinical or pathologic features and outcome. Methods: Samples from patients with advanced UC and correlative clinical data were collected. Genomic imbalances were investigated by array comparative genomic hybridization (aCGH). ALK gene status was evaluated by fluorescence in situ hybridization (FISH). ALK expression was assessed by immunohistochemistry (IHC) and high-throughput mutation analysis with Oncomap 3 platform. Next generation sequencing was performed using Illumina Genome Analyzer IIx, and Illumina HiSeq 2000 in the FISH positive case. Results: 70 of 96 patients had tissue available for all the tests performed. Arm level copy number gains at chromosome 2 were identified in 17 (24%) patients. Minor copy number alterations (CNAs) in the proximity of ALK locus were found in 3 patients by aCGH. By FISH analysis, one of these samples had a deletion of the 5′ALK. Whole genome next generation sequencing was inconclusive to confirm the deletion at the level of the ALK gene at the coverage level used. We did not observe an association between ALK CNA and overall survival, ECOG PS, or development of visceral disease. Conclusions: ALK genomic alterations are rare and probably without prognostic implications in UC. The potential for testing ALK inhibitors in UC merits further investigation but might be restricted to the identification of an enriched population.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118868/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785962
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)